A bill to amend the Internal Revenue Code of 1986 to establish a stewardship fee on the production and importation of opioid pain relievers, and for other purposes.

Introduced in Senate
Budgeting for Opioid Addiction Treatment Act 

This bill amends the Internal Revenue Code, with respect to excise taxes on
manufacturers, to impose a one cent per milligram fee on the sale of active
opioids by the manufacturer, producer, or importer. The fee excludes
prescription drugs used exclusively for the treatment of opioid addiction as
part of a medically assisted treatment effort. 

The Department of Health and Human Services (HHS) must establish a program to
provide rebates or discounts to cancer and hospice patients to ensure that they
do not pay the fee. 

The bill amends the Public Health Service Act to require any increase in federal
revenues from the fee after rebates and discounts are subtracted to be
distributed to states under the Substance Abuse Prevention and Treatment Block
Grant program. The states must use the funds exclusively for substance abuse
(including opioid abuse) efforts in the states, including: (1) specified
treatment programs, and (2) the recruitment and training of substance use
disorder professionals to work in rural and medically underserved communities.

HHS must report to Congress on the impact of this bill on the retail cost of
opioids and patient access to opioid medication, the effectiveness of the
discount or rebate for cancer and hospice patients, how the funds are being used
to improve substance abuse treatment efforts, and suggestions for improving
access to opioids for cancer and hospice patients and substance abuse treatment



  • Read twice and referred to the Committee on Finance.

    Mar 2nd, 2017
  • Introduced in Senate

    Mar 2nd, 2017